| Cancer therapy with TCR-engineered T cells: current strategies, challenges, and prospects P Shafer, LM Kelly, V Hoyos Frontiers in immunology 13, 835762, 2022 | 99 | 2022 |
| Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer SA Nalawade, P Shafer, P Bajgain, MK McKenna, A Ali, L Kelly, J Joubert, ... Journal for immunotherapy of cancer 9 (11), 2021 | 45 | 2021 |
| Interferon gamma mediates hematopoietic stem cell activation and niche relocalization through BST2 MA Florez, KA Matatall, Y Jeong, L Ortinau, PW Shafer, AM Lynch, ... Cell reports 33 (12), 2020 | 38 | 2020 |
| Targeting IDH2R140Q and other neoantigens in acute myeloid leukemia WK Leung, AG Torres Chavez, M French-Kim, P Shafer, M Mamonkin, ... Blood 143 (17), 1726-1737, 2024 | 2 | 2024 |
| Overcoming the breast tumor microenvironment by targeting MDSCs through CAR-T cell therapy. SA Nalawade, P Shafer, P Bajgain, K McKenna, A Ali, L Kelly, J Joubert, ... Journal of Clinical Oncology 39 (15_suppl), 1032-1032, 2021 | 2 | 2021 |
| Abstract PO5-04-06: Enhancing Antitumor Activity of Her2 CAR T cells through TR2BB Co-Expression and Cytokine Signal 3 Incorporation D Chamorro, L Somes, E Madaras, S Nalawade, P Shafer, A Mosquera, ... Cancer Research 84 (9_Supplement), PO5-04-06-PO5-04-06, 2024 | | 2024 |
| Abstract PO4-06-08: ZP4 AS A NOVEL TARGET FOR CAR T CELL THERAPY IN TRIPLE NEGATIVE BREAST CANCER L Somes, J Lei, P Shafer, X Yi, D Chamorro, E Madaras, M Lewis, ... Cancer Research 84 (9_Supplement), PO4-06-08-PO4-06-08, 2024 | | 2024 |
| Incongruity between T cell receptor recognition of breast cancer hotspot mutations ESR1 Y537S and D538G following exogenous peptide loading versus endogenous antigen processing P Shafer, WK Leung, M Woods, JM Choi, CM Rodriguez-Plata, ... Cytotherapy, 2024 | | 2024 |
| Immunotherapy: DISCOVERY OF BREAST CANCER SPECIFIC TCRS COVERING A BROAD RANGE OF COMMON HLA ALLELES P Shafer, JM Choi, WK Leung, A Mosquera, R Yi, B Burt, H Lee, P Lulla, ... Cytotherapy 25 (6), S251, 2023 | | 2023 |
| Pan-cancer proteogenomics expands the landscape of therapeutic targets JT Lei, SR Savage, X Yi, B Wen, H Zhao, LK Somes, PW Shafer, Y Dou, ... Cancer Research 83 (7_Supplement), 5726-5726, 2023 | | 2023 |
| Abstract P6-10-11: Engineered neoantigen-specific T cell receptors to treat metastatic breast cancer P Shafer, WK Leung, ML Woods, C Rodriguez-Plata, A Ali, S Nalawade, ... Cancer Research 83 (5_Supplement), P6-10-11-P6-10-11, 2023 | | 2023 |
| Bone Marrow Stromal Antigen 2 Is Critical for IFNy-Dependent Hematopoietic Stem Cell Activation MA Florez, KA Matatall, Y Jeong, L Ortinau, P Shafer, A Lynch, R Jaksik, ... Blood 136, 2-3, 2020 | | 2020 |
| Overcoming the Breast Tumor Microenvironment by Targeting MDSCs through CAR-T Cell Therapy SA Nalawade, P Shafer, P Bajgain, K McKenna, A Ali, J Joubert, ... MOLECULAR THERAPY 28 (4), 33-34, 2020 | | 2020 |
